Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MARIA BOTTAZZI and ULRICH STRYCH.
MARIA BOTTAZZI
Connection Strength
5.919
ULRICH STRYCH
  1. From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):495-500.
    View in: PubMed
    Score: 0.214
  2. Vaxi-DL: A web-based deep learning server to identify potential vaccine candidates. Comput Biol Med. 2022 06; 145:105401.
    View in: PubMed
    Score: 0.203
  3. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. bioRxiv. 2022 Mar 22.
    View in: PubMed
    Score: 0.203
  4. Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. Protein Expr Purif. 2022 02; 190:106003.
    View in: PubMed
    Score: 0.197
  5. Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. Sci Rep. 2021 09 02; 11(1):17626.
    View in: PubMed
    Score: 0.195
  6. Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1. Appl Microbiol Biotechnol. 2021 May; 105(10):4153-4165.
    View in: PubMed
    Score: 0.191
  7. SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Hum Vaccin Immunother. 2021 08 03; 17(8):2356-2366.
    View in: PubMed
    Score: 0.190
  8. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochim Biophys Acta Gen Subj. 2021 06; 1865(6):129893.
    View in: PubMed
    Score: 0.189
  9. SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice. bioRxiv. 2021 Feb 09.
    View in: PubMed
    Score: 0.188
  10. COVID-19 vaccines: neutralizing antibodies and the alum advantage. Nat Rev Immunol. 2020 07; 20(7):399-400.
    View in: PubMed
    Score: 0.180
  11. Coronavirus vaccine-associated lung immunopathology-what is the significance? Microbes Infect. 2020 10; 22(9):403-404.
    View in: PubMed
    Score: 0.180
  12. The SARS-CoV-2 Vaccine Pipeline: an Overview. Curr Trop Med Rep. 2020; 7(2):61-64.
    View in: PubMed
    Score: 0.176
  13. Process Characterization and Biophysical Analysis for a Yeast-Expressed Phlebotomus papatasi Salivary Protein (PpSP15) as?a Leishmania Vaccine Candidate. J Pharm Sci. 2020 05; 109(5):1673-1680.
    View in: PubMed
    Score: 0.176
  14. Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens. Vaccines (Basel). 2019 Sep 27; 7(4).
    View in: PubMed
    Score: 0.171
  15. A method to probe protein structure from UV absorbance spectra. Anal Biochem. 2019 12 15; 587:113450.
    View in: PubMed
    Score: 0.171
  16. Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. J Pharm Sci. 2018 05; 107(5):1468-1473.
    View in: PubMed
    Score: 0.151
  17. A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations. Vaccine. 2017 03 07; 35(10):1410-1416.
    View in: PubMed
    Score: 0.142
  18. Human anthelminthic vaccines: Rationale and challenges. Vaccine. 2016 06 24; 34(30):3549-55.
    View in: PubMed
    Score: 0.135
  19. Advancing a vaccine to prevent hookworm disease and anemia. Vaccine. 2016 06 03; 34(26):3001-3005.
    View in: PubMed
    Score: 0.134
  20. Advancing a vaccine to prevent human schistosomiasis. Vaccine. 2016 06 03; 34(26):2988-2991.
    View in: PubMed
    Score: 0.134
  21. Status of vaccine research and development of vaccines for Chagas disease. Vaccine. 2016 06 03; 34(26):2996-3000.
    View in: PubMed
    Score: 0.134
  22. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine. 2016 06 03; 34(26):2992-2995.
    View in: PubMed
    Score: 0.134
  23. New Vaccines for the World's Poorest People. Annu Rev Med. 2016; 67:405-17.
    View in: PubMed
    Score: 0.129
  24. The Current and Future Burden of Long COVID in the United States (U.S.). J Infect Dis. 2025 Jan 22.
    View in: PubMed
    Score: 0.062
  25. Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization. Front Immunol. 2024; 15:1480976.
    View in: PubMed
    Score: 0.061
  26. Mechanistic insights into structure-based design of a Lyme disease subunit vaccine. bioRxiv. 2024 Oct 28.
    View in: PubMed
    Score: 0.061
  27. Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins. Viruses. 2024 Sep 20; 16(9).
    View in: PubMed
    Score: 0.060
  28. What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective? J Infect Dis. 2024 Aug 16; 230(2):382-393.
    View in: PubMed
    Score: 0.060
  29. A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses. NPJ Vaccines. 2024 Jul 22; 9(1):132.
    View in: PubMed
    Score: 0.060
  30. Response to: "Quantifying the effect of vaccination on transmission in modelling studies". EClinicalMedicine. 2024 Jul; 73:102670.
    View in: PubMed
    Score: 0.059
  31. The zebrafish as a potential model for vaccine and adjuvant development. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):535-545.
    View in: PubMed
    Score: 0.059
  32. Harnessing RNA Technology to Advance Therapeutic Vaccine Antigens against Chagas Disease. ACS Appl Mater Interfaces. 2024 Apr 03; 16(13):15832-15846.
    View in: PubMed
    Score: 0.058
  33. The potential epidemiologic, clinical, and economic value of a universal coronavirus vaccine: a modelling study. EClinicalMedicine. 2024 Feb; 68:102369.
    View in: PubMed
    Score: 0.058
  34. Biophysical and biochemical characterization of a recombinant Lyme disease vaccine antigen, CspZ-YA. Int J Biol Macromol. 2024 Feb; 259(Pt 2):129295.
    View in: PubMed
    Score: 0.058
  35. A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2. Vaccines (Basel). 2023 Oct 01; 11(10).
    View in: PubMed
    Score: 0.056
  36. Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased level of polyfunctional CD8+ T-cells. Curr Res Immunol. 2023; 4:100066.
    View in: PubMed
    Score: 0.056
  37. A Data-Driven Approach to Construct a Molecular Map of Trypanosoma cruzi to Identify Drugs and Vaccine Targets. Vaccines (Basel). 2023 Jan 26; 11(2).
    View in: PubMed
    Score: 0.054
  38. Vaxi-DL: An Artificial Intelligence-Enabled Platform for Vaccine Development. Methods Mol Biol. 2023; 2673:305-316.
    View in: PubMed
    Score: 0.054
  39. Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights. Expert Rev Vaccines. 2022 10; 21(10):1405-1417.
    View in: PubMed
    Score: 0.052
  40. CspZ FH-Binding Sites as Epitopes Promote Antibody-Mediated Lyme Borreliae Clearance. Infect Immun. 2022 07 21; 90(7):e0006222.
    View in: PubMed
    Score: 0.052
  41. Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study. Lancet Public Health. 2022 04; 7(4):e356-e365.
    View in: PubMed
    Score: 0.051
  42. Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice. Front Immunol. 2022; 13:800295.
    View in: PubMed
    Score: 0.050
  43. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Sci Transl Med. 2022 Jan 26; 14(629):eabj5305.
    View in: PubMed
    Score: 0.050
  44. Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination. J Infect Dis. 2021 09 17; 224(6):938-948.
    View in: PubMed
    Score: 0.049
  45. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 07 15; 6(61).
    View in: PubMed
    Score: 0.048
  46. Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity. bioRxiv. 2021 May 21.
    View in: PubMed
    Score: 0.048
  47. The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine. Am J Prev Med. 2021 05; 60(5):605-613.
    View in: PubMed
    Score: 0.047
  48. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541.
    View in: PubMed
    Score: 0.046
  49. A scalable and reproducible manufacturing process for Phlebotomus papatasi salivary protein PpSP15, a vaccine candidate for leishmaniasis. Protein Expr Purif. 2021 01; 177:105750.
    View in: PubMed
    Score: 0.046
  50. Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. Am J Prev Med. 2020 10; 59(4):493-503.
    View in: PubMed
    Score: 0.045
  51. Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement. bioRxiv. 2020 Jul 05.
    View in: PubMed
    Score: 0.045
  52. How Efficacious Must a COVID-19 Coronavirus Vaccine be to Prevent or Stop an Epidemic by Itself. medRxiv. 2020 May 30.
    View in: PubMed
    Score: 0.045
  53. The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission. Vaccine. 2020 04 03; 38(16):3261-3270.
    View in: PubMed
    Score: 0.044
  54. Protective immunity elicited by the nematode-conserved As37 recombinant protein against Ascaris suum infection. PLoS Negl Trop Dis. 2020 02; 14(2):e0008057.
    View in: PubMed
    Score: 0.044
  55. Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. Vaccine. 2019 06 19; 37(28):3704-3714.
    View in: PubMed
    Score: 0.042
  56. Covalent vaccination with Trypanosoma cruzi Tc24 induces catalytic antibody production. Parasite Immunol. 2018 Nov; 40(11):e12585.
    View in: PubMed
    Score: 0.040
  57. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018 03 27; 36(14):1853-1862.
    View in: PubMed
    Score: 0.038
  58. Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response. PLoS Negl Trop Dis. 2017 Jul; 11(7):e0005769.
    View in: PubMed
    Score: 0.037
  59. Mutations to Cysteine Residues in the Trypanosoma cruzi B-Cell Superantigen Tc24 Diminish Susceptibility to IgM-Mediated Hydrolysis. J Parasitol. 2017 10; 103(5):579-583.
    View in: PubMed
    Score: 0.036
  60. Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. J Pharm Sci. 2017 08; 106(8):1961-1970.
    View in: PubMed
    Score: 0.036
  61. Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Hum Vaccin Immunother. 2017 03 04; 13(3):621-633.
    View in: PubMed
    Score: 0.035
  62. The hookworm Ancylostoma ceylanicum intestinal transcriptome provides a platform for selecting drug and vaccine candidates. Parasit Vectors. 2016 Sep 27; 9(1):518.
    View in: PubMed
    Score: 0.035
  63. Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties. Hum Vaccin Immunother. 2016 07 02; 12(7):1707-20.
    View in: PubMed
    Score: 0.033
  64. Neglected tropical diseases among the Association of Southeast Asian Nations (ASEAN): overview and update. PLoS Negl Trop Dis. 2015 Apr; 9(4):e0003575.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.